Related Experiment Video

Updated: Jun 13, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

George D Demetri1, Margaret von Mehren, Cristina R Antonescu

  • 1Ludwig Center at Dana-Farber/Harvard Cancer Center, USA.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 12, 2010
PubMed

Insights

Gastrointestinal stromal tumors (GISTs) management has evolved with targeted therapies like tyrosine kinase inhibitors (TKIs). Experts convened to discuss advances in GIST diagnosis, treatment resistance, and optimal patient care strategies.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Gastroenterology

Background:

  • The management of gastrointestinal stromal tumors (GISTs) has been revolutionized by molecularly targeted therapies, specifically tyrosine kinase inhibitors (TKIs) like imatinib mesylate and sunitinib malate.
  • Advances in understanding GIST molecular characteristics have enhanced diagnostic accuracy and identified novel immunomarkers.
  • New insights into mechanisms of resistance to TKI therapy have spurred the development of innovative treatment strategies.

Framework:

  • A multidisciplinary task force, including experts in medical oncology, surgical oncology, molecular diagnostics, and pathology, was convened by the National Comprehensive Cancer Network (NCCN).
  • The task force aimed to discuss recent scientific advances, pinpoint areas for future research, and formulate recommendations for optimal patient care across all stages of GIST.
  • Meetings were held in October 2003, December 2006, and October 2009 to address these critical issues.

Implementation:

  • The NCCN task force synthesized recent developments in GIST management.
  • Discussions focused on improving diagnostic accuracy and understanding TKI resistance mechanisms.
  • Recommendations for optimal patient care were developed based on expert consensus.

Implications:

  • The evolving landscape of GIST treatment necessitates updated clinical guidelines and management strategies.
  • Continued research into molecular characteristics and resistance mechanisms is crucial for further therapeutic advancements.
  • Multidisciplinary collaboration is essential for providing comprehensive and effective care for patients with GIST.

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...